However, the low detection rate of common driver gene mutations, such as EGFR and ALK, in patients with comorbid IP frequently results in inadequate screening for driver mutations, and KRAS mutations may be unintentionally overlooked. This evidence concerns the gene EGFR and incontinentia pigmenti.